Oculis Holding AG priced a $110 million equity offering on October 30, 2025, at $20.25 per share. The offering is oversubscribed and includes 4,691,358 shares in an underwritten offering and 740,740 shares in a direct offering, with an option for underwriters to purchase an additional 703,703 shares. The new shares increase the company’s authorized shares to 57,169,475.
Net proceeds will be used to accelerate the development of Privosegtor for acute optic neuritis and non‑arteritic anterior ischemic optic neuropathy, to fund working capital and general corporate purposes, and to extend the company’s cash runway into the second half of 2027. The offering is expected to close on or about November 3, 2025.
Privosegtor has shown promising Phase 2 results for acute optic neuritis, has received orphan drug designation from the FDA and EMA, and has entered a registrational program following a positive FDA meeting. Oculis also continues development of other late‑stage candidates, including OCS‑01 for diabetic macular edema and Licaminlimab for dry eye disease.
The company has previously raised capital through equity offerings, including a $40.25 million offering in May 2023 and a $100 million offering in February 2025. An at‑the‑market prospectus that could have allowed sales of up to $100 million of ordinary shares was suspended and terminated with no shares sold. Oculis has reported losses in recent quarters but has maintained a positive trend in its financial performance.
The equity offering provides Oculis with additional liquidity to support its late‑stage pipeline and maintain its cash runway into 2H 2027, reinforcing its ability to pursue clinical milestones and potentially bring its neuroprotective therapy to market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.